Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel cash
Cash and short-term investments held at the end of each period.
Vericel's cash was $170.27M at Sep 30, 2026. For fiscal 2025 it was $137.50M, up 8.5% from the year before. Over ten years it grew 25.2% a year on average. The highest annual figure on record is $137.50M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.50M | +8.5% |
| FY2024 | Dec 31, 2024 | $126.74M | +15.7% |
| FY2023 | Dec 31, 2023 | $109.56M | -8.3% |
| FY2022 | Dec 31, 2022 | $119.54M | +15.4% |
| FY2021 | Dec 31, 2021 | $103.61M | +36.3% |
| FY2020 | Dec 31, 2020 | $76.02M | +8.9% |
| FY2019 | Dec 31, 2019 | $69.81M | -15.8% |
| FY2018 | Dec 31, 2018 | $82.92M | +208.7% |
| FY2017 | Dec 31, 2017 | $26.86M | +16.9% |
| FY2016 | Dec 31, 2016 | $22.98M | +57.6% |
| FY2015 | Dec 31, 2015 | $14.58M | -51.9% |
| FY2014 | Dec 31, 2014 | $30.34M | +276.5% |
| FY2013 | Dec 31, 2013 | $8.06M | -40.9% |
| FY2012 | Dec 31, 2012 | $13.64M | -3.4% |
| FY2010 | Jun 30, 2010 | $14.12M | -16.9% |
| FY2009 | Jun 30, 2009 | $17.00M | +3.1% |
| FY2008 | Jun 30, 2008 | $16.49M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $170.27M | +25.8% |
| Q2 FY2026 | Jun 30, 2026 | $162.46M | +39.0% |
| Q1 FY2026 | Mar 31, 2026 | $145.34M | +28.7% |
| Q4 FY2025 | Dec 31, 2025 | $137.50M | +8.5% |
| Q3 FY2025 | Sep 30, 2025 | $135.38M | +33.1% |
| Q2 FY2025 | Jun 30, 2025 | $116.88M | +14.0% |
| Q1 FY2025 | Mar 31, 2025 | $112.90M | +2.0% |
| Q4 FY2024 | Dec 31, 2024 | $126.74M | +15.7% |
| Q3 FY2024 | Sep 30, 2024 | $101.73M | -3.4% |
| Q2 FY2024 | Jun 30, 2024 | $102.51M | +4.8% |
| Q1 FY2024 | Mar 31, 2024 | $110.65M | -7.2% |
| Q4 FY2023 | Dec 31, 2023 | $109.56M | -8.3% |
| Q3 FY2023 | Sep 30, 2023 | $105.34M | -5.0% |
| Q2 FY2023 | Jun 30, 2023 | $97.83M | -2.8% |
| Q1 FY2023 | Mar 31, 2023 | $119.28M | +18.6% |
| Q4 FY2022 | Dec 31, 2022 | $119.54M | +15.4% |
| Q3 FY2022 | Sep 30, 2022 | $110.94M | +12.9% |
| Q2 FY2022 | Jun 30, 2022 | $100.69M | +10.7% |
| Q1 FY2022 | Mar 31, 2022 | $100.55M | +20.3% |
| Q4 FY2021 | Dec 31, 2021 | $103.61M | +36.3% |
| Q3 FY2021 | Sep 30, 2021 | $98.29M | +14.9% |
| Q2 FY2021 | Jun 30, 2021 | $90.98M | +12.6% |
| Q1 FY2021 | Mar 31, 2021 | $83.56M | +2.4% |
| Q4 FY2020 | Dec 31, 2020 | $76.02M | +8.9% |
| Q3 FY2020 | Sep 30, 2020 | $85.54M | +14.6% |
| Q2 FY2020 | Jun 30, 2020 | $80.79M | +22.3% |
| Q1 FY2020 | Mar 31, 2020 | $81.58M | -3.0% |
| Q4 FY2019 | Dec 31, 2019 | $69.81M | -15.8% |
| Q3 FY2019 | Sep 30, 2019 | $74.66M | -23.6% |
| Q2 FY2019 | Jun 30, 2019 | $66.05M | -30.5% |
| Q1 FY2019 | Mar 31, 2019 | $84.09M | +182.4% |
| Q4 FY2018 | Dec 31, 2018 | $82.92M | +208.7% |
| Q3 FY2018 | Sep 30, 2018 | $97.75M | +532.0% |
| Q2 FY2018 | Jun 30, 2018 | $94.97M | +576.4% |
| Q1 FY2018 | Mar 31, 2018 | $29.78M | +50.0% |
| Q4 FY2017 | Dec 31, 2017 | $26.86M | +16.9% |
| Q3 FY2017 | Sep 30, 2017 | $15.47M | – |
| Q2 FY2017 | Jun 30, 2017 | $14.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $19.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.98M | – |
See a number that looks wrong?